Navigation Links
ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes
Date:3/14/2010

Lowering blood pressure to normal levels below currently recommended levels did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events in adults with type 2 diabetes who were at especially high risk for cardiovascular disease events, according to new results from the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial. Similarly, treating multiple blood lipids with combination drug therapy of a fibrate and a statin did not reduce the combined risk of cardiovascular disease events more than treatment with statin alone. The study of more than 10,000 participants is sponsored by the National Institutes of Health.

ACCORD is one of the largest studies ever conducted in adults with type 2 diabetes who were at especially high risk of cardiovascular events, such as heart attacks, stroke, or death from cardiovascular disease. The multicenter clinical trial tested three potential strategies to lower the risk of major cardiovascular events: intensive control of blood sugar, intensive control of blood pressure, and treatment of multiple blood lipids. The lipids targeted for intensive treatment were high density lipoprotein (HDL) cholesterol and triglycerides, in addition to standard therapy of lowering low density lipoprotein (LDL) cholesterol.

The results of the ACCORD blood pressure and lipid clinical trials appear online in the New England Journal of Medicine (NEJM) today and will be in the April 29, 2010, NEJM print edition. The results are also being presented today at the American College of Cardiology's 59th annual scientific session in Atlanta. Results of the ACCORD blood sugar clinical trial were reported in 2008.

"ACCORD provides important evidence to help guide treatment recommendations for adults with type 2 diabetes who have had a heart attack or stroke or who are otherwise at especially high risk for cardiovascular disease," said Susan B. Shurin, M.D., actin
'/>"/>

Contact: NHLBI Communications Office
nhlbi_news@nhlbi.nih.gov
301-496-4236
NIH/National Heart, Lung and Blood Institute
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. Risk for patients in the intensive care unit clearly reduced
2. Texas Girl Recovers From Rabies Without Intensive Care
3. Short on specialized intensive care physicians, team-based approach improves ICU outcomes
4. Intensive Insulin Therapy Wont Boost Septic Shock Survival
5. Intensive Rectal Cancer Treatment Shows Promise
6. The Breema Center Announces Its Winter Intensive
7. Intensive Dialysis Doesnt Save Lives of the Sickest
8. Intensive care units poorly equipped to care for the dying
9. University Medical Center Mainz Completes Installation of Masimo Noninvasive and Continuous Hemoglobin Throughout Their Operating Rooms, Intensive Care Units and Emergency Department
10. Integrated Medical Systems Receives CE Mark for Worlds First Suitcase Intensive Care Unit
11. The Breema Center Presents Its Fall Week-Long Intensive on Giving and Receiving Breema Bodywork
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Decene is an ... chain of ten carbon atoms with one double ... of 1-decenes. It can be used as a ... to produce epoxides, amines, oxo alcohols, synthetic lubricants, ... Early buyers will receive 10% customization on this ...
(Date:7/30/2014)... 2014 Naomi Fried, PhD, and ... of Directors of the American Telemedicine Association (ATA). ... which has a mission to promote professional, ethical ... and information technology. , “Both Naomi Fried and ... extraordinary expertise and are well known experts in ...
(Date:7/30/2014)... 2014 (HealthDay News) -- Clues to whether a person is ... test, a new study suggests. Chemical changes to a ... help spur suicidal thoughts and behaviors, the study,s authors explained. ... doctors to a patient,s risk for suicide, they said. ... have been stymied in our prevention efforts because we have ...
(Date:7/30/2014)... 2014 The global digital pathology market was ... expected to grow at a CAGR of 11.8%, to reach ... digital pathology is growing and is expected to continue to ... scanners and image analysis software enable pathologists to be efficient ... In 2013, the North American market was valued at $128.9 ...
(Date:7/30/2014)... This news release is available in French . ... Inserm, led by Claude Gronfier (Inserm Unit 846: Stem ... conducted a study under real conditions on the body ... Concordia. The researchers have shown that a particular kind ... biological rhythms are correctly synchronised despite the absence of ...
Breaking Medicine News(10 mins):Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 2Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 3Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 4Health News:American Telemedicine Association Welcomes Two New Members to the Board of Directors 2Health News:Could a Blood Test Predict Suicide Risk? 2Health News:Could a Blood Test Predict Suicide Risk? 3Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 2Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 3Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 4Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 5Health News:Dimly lit working environments: Correcting your body clock is possible! 2Health News:Dimly lit working environments: Correcting your body clock is possible! 3Health News:Dimly lit working environments: Correcting your body clock is possible! 4
... impairment that strikes in the early stages of prion diseases such ... ,The findings suggest there may be a way to cure ... before it has time to kill off large numbers of brain ... lives of 158 people in Britain, and seven more are known ...
... recently discovered genes from an ancient wheat variety have led ... ,In a recent set of papers published in the ... as Nax1 and Nax2. The genes work by excluding salt ... the other from the leaves. The discovery of the two ...
... is a neighborhood which renders immense potential to walk around, ... revealed in a survey conducted by// Ethan Berke of Dartmouth ... for publication in the March issue of American Journal of ... group of 65-97. Some of the parameters that were analyzed ...
... more slowly in women and older adults, a new study at ... to the skin heal more quickly in women than in men, ... inside the mouth," said Dr. Phillip Marucha, head of periodontics at ... of age, men's mouth wounds heal faster than women's." ...
... practice guidelines for diagnosis and management of venous thromboembolism.// ... clotting in the veins. ,Key elements of ... rules to establish pretest probability of deep vein thrombosis ... and the utility of various diagnostic tools such as ...
... the application filed before the Hon’ble Supreme Court, the ... to ST candidates in the All India Quota seats ... session 2007-08. While disposing of this application for directions ... case Vs Union of India, WP 18/2006, Hon’ble Supreme ...
Cached Medicine News:Health News:Researchers Make Strides in VCJD Detection 2Health News:Ancient Genes Used to Produce Salt-Tolerant Wheat 2Health News:Oral Wounds Heal Slower in Women, Older Adults 2Health News:New Guidelines for Diagnosis of Venous Thromboembolism 2
(Date:7/30/2014)... DIEGO , July 30, 2014   ... biotech company that designs and develops novel diagnostics ... of cancer, announced today the completion of a ... financing included new investors RusnanoMedInvest (RMI) and Arcus ... and Pfizer Venture Investments, as well as undisclosed ...
(Date:7/30/2014)... , 30. Juli 2014 ... ein führender Anbieter im Bereich Atemtherapie- und ... des Landgerichts München in Deutschland anfechten werden. ... bestimmten Masken ein Patent von ResMed verletze. ... in wichtigen Ländern gegen verschiedene Patente von ...
(Date:7/29/2014)... Amgen (NASDAQ: AMGN ) today ... Key results include: , Total revenues increased 11 ... growth driven by strong performance across the portfolio, particularly ... ® (denosumab) and XGEVA ® (denosumab). ... by higher revenues and a significant increase in the ...
Breaking Medicine Technology:Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25
... SUNNYVALE, Calif., Dec. 28, 2010 Accuray Incorporated (Nasdaq: ... radiosurgery, announced today that its president and chief executive officer, ... 29th Annual J.P. Morgan Healthcare Conference in San Francisco on ... A live webcast of the presentation will be ...
... Medical Group Inc. (Nasdaq: WWIN ), ("Winner ... and non-woven fabric made from 100% natural PurCotton® products ... was recently held by Winner Medical and Cotton Incorporated ... in a high footprint shopping mall in Shanghai. ...
Cached Medicine Technology:Accuray Incorporated's CEO to Speak at 29th Annual J.P. Morgan Healthcare Conference 2Winner Medical and Cotton Inc. Promote PurCotton(R) Brand and Natural(TM) Trademark in Shanghai 2Winner Medical and Cotton Inc. Promote PurCotton(R) Brand and Natural(TM) Trademark in Shanghai 3Winner Medical and Cotton Inc. Promote PurCotton(R) Brand and Natural(TM) Trademark in Shanghai 4
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Medicine Products: